Advertisement

European Child & Adolescent Psychiatry

, Volume 15, Issue 8, pp 476–495 | Cite as

Long-acting medications for the hyperkinetic disorders

A systematic review and European treatment guideline
  • Tobias Banaschewski
  • David Coghill
  • Paramala Santosh
  • Alessandro Zuddas
  • Philip Asherson
  • Jan Buitelaar
  • Marina Danckaerts
  • Manfred Döpfner
  • Stephen V. Faraone
  • Aribert Rothenberger
  • Joseph Sergeant
  • Hans-Christoph Steinhausen
  • Edmund J.S. Sonuga-Barke
  • Eric Taylor
ORIGINAL CONTRIBUTIONS

Abstract

A systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder is reported, giving effect sizes and numbers-to-treat for extended-release stimulant preparations and atomoxetine (ATX). A panel of experts from several European countries used the review to make recommendations about the use of these drugs in practice, and conclusions are reported: (1) Long-acting preparations should be available and used; (2) They should not replace short-acting drugs (which will be the initial treatment for many children for reasons of cost and flexibility of dosing). Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made.

Keywords

guidelines review stimulants atomoxetine ADHD 

Notes

Acknowledgements

The authors’ meeting was funded by equal contributions from several companies. The authors’ expenses for travel were paid but they received no fees. Some had potential competing interests, and these are detailed separately (appendix 2).

References

  1. 1.
    Adler LA, Spencer TJ, Milton DR, Moore RJ, Michelson D (2005) Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry 66:294–299PubMedCrossRefGoogle Scholar
  2. 2.
    Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, Winner PK, Dunn DW, Dure LS, Sallee FR, Milton DR, Mintz MI, Ricardi RK, Erenberg G, Layton LL, Feldman PD, Kelsey DK, Spencer TJ (2005) Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 65:1941–1949PubMedCrossRefGoogle Scholar
  3. 3.
    Bangs ME, Hazell P, Danckaerts M, Williams D, Moore RJ, Levine L (2006) Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder in children and adolescents (accepted for oral presentation). 159th Annual Meeting of the American Psychiatric Association. Atlanta, GAGoogle Scholar
  4. 4.
    Bangs ME, Tauscher-Wisniewski S, Polzer J, Zhang S, Acharya N, Desaiah D, Allen AJ (2005) Meta-analysis of suicide-related events in atomoxetine-treated patients (Poster). 52nd Annual AACAP Meeting, TorontoGoogle Scholar
  5. 5.
    Biederman J, Mick E, Faraone SV (2000) Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 157:816–818PubMedCrossRefGoogle Scholar
  6. 6.
    Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T (2005) a randomized, placebo-controlled trial of oros methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 59:829–835PubMedCrossRefGoogle Scholar
  7. 7.
    Biederman J, Quinn D, Weiss M, Markabi S, Weidenman M, Edson K, Karlsson G, Pohlmann H, Wigal S (2003) Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs 5:833–841PubMedCrossRefGoogle Scholar
  8. 8.
    Clarke SA, Eiser C (2004) The measurement of health-related quality of life (QoL) in paediatric clinical trials: a systematic review. Health Qual Life Outcomes 2:66PubMedCrossRefGoogle Scholar
  9. 9.
    Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni RH Jr (2002) Psychopharmacology and aggression. I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry 41:253–261PubMedCrossRefGoogle Scholar
  10. 10.
    Döpfner M, Banaschewski T, Schmidt J, Uebel H, Schmeck K, Gerber WD, Günther M, Knölke U, Gehrke M, Häßler F, Resch F, Brünger M, Ose C, Fischer R, Poustka A, Rothenberger A, Lehmkuhl G (2003) Langzeitwirksames Methylphenidat bei Kindern mit Aufmerksamkeits-Hyperaktivitätsstörungen. Nervenheilkunde 22:85–92Google Scholar
  11. 11.
    Döpfner M, Gerber WD, Banaschewski T, Breuer D, Freisleder FJ, Gerber-von Muller G, Gunter M, Hassler F, Ose C, Rothenberger A, Schmeck K, Sinzig J, Stadler C, Uebel H, Lehmkuhl G (2004) Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry 13(Suppl 1):I93–101PubMedGoogle Scholar
  12. 12.
    Faraone SV, Biederman J (2004) Using meta-analysis to draw conclusions about ADHD medication effects. 17th ECNP Congress. StockholmGoogle Scholar
  13. 13.
    Faraone SV, Biederman J, Mick E (in press) The age dependent decline of attention-deficit/hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 36:159–165Google Scholar
  14. 14.
    Faraone SV, Biederman J, Spencer T, Aleardi M, Pagano C (2003) Using a meta-analysis to draw conclusions about ADHD medication effects (Poster). 156th Annual Meeting of the American Psychiatric Association. San Francisco, CaliforniaGoogle Scholar
  15. 15.
    Faraone SV, Biederman J, Spencer T, Aleardi M, Pagano C, META-ANALYSIS CTEOMFAU (in press) Comparing the efficacy of medications for ADHD using meta-analysisGoogle Scholar
  16. 16.
    Faraone SV, Biederman J, Spencer T, Wilens T, Seidman LJ, Mick E, Doyle AE (2000) Attention-deficit/hyperactivity disorder in adults: an overview. Biol Psychiatry 48:9–20PubMedCrossRefGoogle Scholar
  17. 17.
    Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J (2004) Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 24:24–29PubMedCrossRefGoogle Scholar
  18. 18.
    Findling RL, Quinn D, Hatch S, Cameron S, DeCory H, McDowell M (submitted) Comparison of the clinical efficacy of twice-daily Ritalin®) and once-daily Equasym® XL with placebo in children with attention-deficit/hyperactivity disorder. Data on file UCB, submittedGoogle Scholar
  19. 19.
    Fischer M, Barkley RA, Smallish L, Fletcher K (2002) Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol 30:463–475PubMedCrossRefGoogle Scholar
  20. 20.
    Geddes J, Butler R (2002) Depressive disorders. Clin Evid 7:867–882PubMedGoogle Scholar
  21. 21.
    Gonzalez MA, Pentikis HS, Anderl N, Benedict MF, DeCory HH, Dirksen SJ, Hatch SJ (2002) Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 40:175–184PubMedGoogle Scholar
  22. 22.
    Greenhill L, Vitiello B, Abikoff H, Kollins S, Wigal S, Swanson J (2004) Outcome results from the NIMH, multi-site, preschool ADHD treatment study (PATS). 51th Annual MCAP meeting, Washington, DCGoogle Scholar
  23. 23.
    Greenhill LL, Findling RL, Swanson JM (2002) A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 109:E39PubMedCrossRefGoogle Scholar
  24. 24.
    Jasinski DR, Faries D, Moore RJ, Allen AJ (2004) Abuse liability assessment of atomoxetine in a drug-abusing population. In: CINP; Abstract in Int J Neuropsychopharmacol 7, Suppl. 1, June 2004, p. S310Google Scholar
  25. 25.
    Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF (2004) Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord 8:45–52PubMedGoogle Scholar
  26. 26.
    Kelsey D, Sutton V, Lewis D, Schuh K, Sumner C, Quintana H (2005) Morning- versus evening-dosed atomoxetine: effects on core ADHD symptoms. 158th Annual Meeting of the American Psychiatric Association. Atlanta, GAGoogle Scholar
  27. 27.
    Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ (2004) Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 114:e1–e8PubMedCrossRefGoogle Scholar
  28. 28.
    Kemner JE, Wan GJ (2003) Increased persistency with once-daily OROS®Methylphenidate: an analysis of healthcare claims. 16th US Psychiatric & Mental Health Congress, Orlando, FLGoogle Scholar
  29. 29.
    Kimko HC, Cross JT, Abernethy DR (1999) Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 37:457–470PubMedCrossRefGoogle Scholar
  30. 30.
    King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R (2004) Methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children (commercial in confidence information removed); produced by the Centre for Reviews and Dissemination (CRD). http://www.nice.org.uk/pdf/ADHD_assessment_report.pdf
  31. 31.
    Klassen AF, Miller A, Fine S (2004) Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 114:e541–e547PubMedCrossRefGoogle Scholar
  32. 32.
    Kollins SH, Rush CR, Pazzaglia PJ, Ali JA (1998) Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 6:367–374PubMedCrossRefGoogle Scholar
  33. 33.
    Kratochvil CJ, Greenhill LL, March JS, Burke WJ, Vaughan BS (2004) The role of stimulants in the treatment of preschool children with attention-deficit hyperactivity disorder. CNS Drugs 18:957–966PubMedCrossRefGoogle Scholar
  34. 34.
    Lage M, Hwang P (2004) Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc Psychopharmacol 14:575–581PubMedCrossRefGoogle Scholar
  35. 35.
    Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:51–68PubMedCrossRefGoogle Scholar
  36. 36.
    Lopez F, Silva R, Pestreich L, Muniz R (2003) Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs 5:545–555PubMedCrossRefGoogle Scholar
  37. 37.
    Lopez FA, Chandler MC, Biederman J, Spencer T, Mays DA, Michaels MA, Tulloch SJ (2003) Long-term Adderall XR treatment improves quality of life in ADHD children. 156th Annual Meeting of the American Psychiatric Association, San Francisco, CaliforniaGoogle Scholar
  38. 38.
    Marchetti A, Magar R, Lau H, Murphy EL, Jensen PS, Conners CK, Findling R, Wineburg E, Carotenuto I, Einarson TR, Iskedjian M (2001) Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther 23:1904–1921PubMedCrossRefGoogle Scholar
  39. 39.
    Markowitz JS, Straughn AB, Patrick KS, DeVane CL, Pestreich L, Lee J, Wang Y, Muniz R (2003) Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet 42:393–401PubMedCrossRefGoogle Scholar
  40. 40.
    Matza LS, Rentz AM, Secnik K, Swensen AR, Revicki DA, Michelson D, Spencer T, Newcorn JH, Kratochvil CJ (2004) The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr 25:166–174PubMedCrossRefGoogle Scholar
  41. 41.
    McCabe SE, Teter CJ, Boyd CJ, Knight JR, Wechsler H (2005) Non-medical use of prescription opioids among U.S. college students: prevalence and correlates from a national survey. Addict Behav 30:789–805PubMedCrossRefGoogle Scholar
  42. 42.
    McGough JJ, Biederman J, Greenhill LL, McCracken JT, Spencer TJ, Posner K, Wigal S, Gornbein J, Tulloch S, Swanson JM (2003) Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. J Am Acad Child Adolesc Psychiatry 42:684–691PubMedCrossRefGoogle Scholar
  43. 43.
    Michelson D (2004) Results from a double-blind study of atomoxetine, OROS methylphenidate, and placebo. Scientific Proceedings of the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, 20D, p. 49Google Scholar
  44. 44.
    Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112–120PubMedCrossRefGoogle Scholar
  45. 45.
    MTA-Cooperative-Group (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal treatment study of children with ADHD. Arch Gen Psychiatry 56:1073–1086CrossRefGoogle Scholar
  46. 46.
    Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D (2005) Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 44:240–248PubMedCrossRefGoogle Scholar
  47. 47.
    Palumbo D, Spencer T, Lynch J, Co-Chien H, Faraone SV (2004) Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol 14:185–194PubMedCrossRefGoogle Scholar
  48. 48.
    Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD (2001) Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:E105PubMedCrossRefGoogle Scholar
  49. 49.
    Perwien AR, Faries DE, Kratochvil CJ, Sumner CR, Kelsey DK, Allen AJ (2004) Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. J Dev Behav Pediatr 25:264–271PubMedCrossRefGoogle Scholar
  50. 50.
    Rasmussen P, Gillberg C (2000) Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J Am Acad Child Adolesc Psychiatry 39:1424–1431PubMedCrossRefGoogle Scholar
  51. 51.
    Read HA, Bangs ME, Jin L, Zhang S, Allen AJ (2005) Review of hepatic events associated with atomoxetine treatment in ADHD. 52nd Annual AACAP Meeting. TorontoGoogle Scholar
  52. 52.
    Rentz AM, Matza LS, Secnik K, Swensen A, Revicki DA (2005) Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/hyperactivity disorder. Qual Life Res 14:719–734PubMedCrossRefGoogle Scholar
  53. 53.
    SAMHSA (US Department of Health and Human Services—Substance Abuse & Mental Health Service Administration) (2005) US National Survey on Drug Use and Health 2004. http://www.oas.samhsa.gov/p0000016.htm#2k4
  54. 54.
    SIGN (Scottish Intercoligiate Guidelines Networt) (2001) Attention deficit and hyperkinetic disorders in children and young people: a national clinical guideline. Vol. 52. EdinburghGoogle Scholar
  55. 55.
    SIGN (Scottish Intercoligiate Guidelines Networt) (2004) A guidelines developer’s handbook. SIGN, EdinburghGoogle Scholar
  56. 56.
    Simpson D, Plosker GL (2004) Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 64:205–222PubMedCrossRefGoogle Scholar
  57. 57.
    Sinzig JK, Döpfner M, Pluck J, Banaschewski T, Stephani U, Lehmkuhl G, Rothenberger A (2004) [Does a morning dose of Methylphenidate Retard reduce hyperkinetic symptoms in the afternoon?]. Z Kinder Jugendpsychiatr Psychother 32:225–233PubMedCrossRefGoogle Scholar
  58. 58.
    Sonuga-Barke E, Daley D, Thompson MJS (2003) The management of preschool AD/HD; Addressing uncertainties about syndrome validity, diagnostic utility and treatment safety. Expert Rev Neurotherapeutics 3:89–100CrossRefGoogle Scholar
  59. 59.
    Sonuga-Barke EJ, Auerbach J, Campbell SB, Daley D, Thompson M (2005) Varieties of preschool hyperactivity: multiple pathways from risk to disorder. Dev Sci 8:141–150PubMedCrossRefGoogle Scholar
  60. 60.
    Sonuga-Barke EJ, Swanson JM, Coghill D, DeCory HH, Hatch SJ (2004) Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 4:28PubMedCrossRefGoogle Scholar
  61. 61.
    Soomro GM (2002) Obsessive-compulsive disorder. Clin Evid 7:896–905PubMedGoogle Scholar
  62. 62.
    Spencer T, Abikoff H, Connor DF, Biederman J, Pliszka S, Boellner S, Read SC, Pratt R (2006) The safety and efficacy of mixed amphetamine salts extended release Adderall XR in the Management of oppositional defiant disorder (ODD) with or without comorbid attention deficit hyperactivity disorder (ADHD) in School-age Children and Adolescents. Clin Ther 28:402–418PubMedCrossRefGoogle Scholar
  63. 63.
    Spencer T, Biederman J, Abikoff HB, Pliszka SR, Boellner SW, Lopez FA, Read SC, Tulloch SJ (2004) Safety and efficacy of mixed amphetamine salts extended release in children and adolescents with oppositional defiant disorder (ODD). 157th Annual Meeting of the American Psychiatric Association, New YorkGoogle Scholar
  64. 64.
    Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S (2005) A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 57:456–463PubMedCrossRefGoogle Scholar
  65. 65.
    Steele M, Weiss M, Swanson J, Wang J, Prinzo R, Binder C (2006) A randomized, controlled effectiveness trail of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in ADHD. Can J Clin Pharmacol 13:e50–62PubMedGoogle Scholar
  66. 66.
    Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH (2003) A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 112:e404PubMedCrossRefGoogle Scholar
  67. 67.
    Sumner C, Donnelly C, Lopez FA, Sutton V, Bakken R, Paczkowski M, Kelsey D (2005) Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety. 158th Annual Meeting of the American Psychiatric Association. Atlanta, GAGoogle Scholar
  68. 68.
    Swanson J, Greenhill L, Pelham W, Wilens T, Wolraich M, Abikoff H, Atkins M, August G, Biederman J, Bukstein O, Conners CK, Efron L, Fiebelkorn K, Fried J, Hoffman M, Lambrecht L, Lerner M, Leventhal B, McBurnett K, Morse E, Palumbo D, Pfiffner L, Stein M, Wigal SB, Winans E (2000) Initiating Concerta TM (Oros® methylphenidate HCl) qu in children with attention-deficit hyperactivity disorder. J Clin Res 3:59–76Google Scholar
  69. 69.
    Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Lindemulder E, Wigal S (2003) Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 60:204–211PubMedCrossRefGoogle Scholar
  70. 70.
    Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ (2004) A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 113:e206–e216PubMedCrossRefGoogle Scholar
  71. 71.
    Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A (2004) European clinical guidelines for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):I7–30PubMedGoogle Scholar
  72. 72.
    Tourette-Syndrome-Study-Group (2002) Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58:527–536Google Scholar
  73. 73.
    Volkow ND, Fowler JS, Wang GJ, Swanson JM (2004) Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 9:557–569PubMedCrossRefGoogle Scholar
  74. 74.
    Wan GJ, Cooper KM (2004) Reduced symptoms of opposition and defiance in children with attention-deficit/hyperactivity disorder treated with methylphenidate. 17th US Psychiatric & Mental Health Congress, 2004, San Diego, CAGoogle Scholar
  75. 75.
    Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ (2005) A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 44:647–655PubMedCrossRefGoogle Scholar
  76. 76.
    Wigal SB, McGough JJ, McCracken JT, Biederman J, Spencer TJ, Posner KL, Wigal TL, Kollins SH, Clark TM, Mays DA, Zhang Y, Tulloch SJ (2005) A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 9:275–289PubMedCrossRefGoogle Scholar
  77. 77.
    Wilens T, Gignac M, Sweezey A, Monuteaux M, Biederman J (2006) Characteristics of Adolescents and Young Adults with ADHD Who Divert or Misuse their Prescribed Medications. J Am Acad Child Adolesc Psychiatry 45:408–414PubMedCrossRefGoogle Scholar
  78. 78.
    Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M (2005) ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 44:1015–1023PubMedCrossRefGoogle Scholar
  79. 79.
    Wilens TE (2003) Does the medicating ADHD increase or decrease the risk for later substance abuse? Rev Bras Psiquiatr 25:127–128PubMedCrossRefGoogle Scholar
  80. 80.
    Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G (2001) Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108:883–892PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2006

Authors and Affiliations

  • Tobias Banaschewski
    • 1
  • David Coghill
    • 2
  • Paramala Santosh
    • 3
    • 4
  • Alessandro Zuddas
    • 5
  • Philip Asherson
    • 6
  • Jan Buitelaar
    • 7
  • Marina Danckaerts
    • 8
  • Manfred Döpfner
    • 9
  • Stephen V. Faraone
    • 10
  • Aribert Rothenberger
    • 1
  • Joseph Sergeant
    • 11
  • Hans-Christoph Steinhausen
    • 12
  • Edmund J.S. Sonuga-Barke
    • 13
  • Eric Taylor
    • 14
  1. 1.Dept. of Child & Adolescent Psychiatry/PsychotherapyUniversity of GoettingenGoettingenGermany
  2. 2.Dept. of PsychiatryUniversity of DundeeDundeeUK
  3. 3.Dept. of Psychological MedicineHospital for ChildrenLondonUK
  4. 4.Institute of PsychiatryMaudsley HospitalLondonUK
  5. 5.Child Neuropsychiatry, Dept. NeuroscienceUniversity of CagliariCagliariItaly
  6. 6.MRC Social Genetic & Developmental Research Centre, Institute of PsychiatryKings College LondonLondonUK
  7. 7.Dept. of PsychiatryAcademic Centre for Child & Adolescent PsychiatryNijmegenThe Netherlands
  8. 8.Dept. Child & Adolescent PsychiatryU. Z. GasthuisbergLeuvenBelgium
  9. 9.Psychiatry and Psychotherapy of Childhood & AdolescenceUniversity of CologneKölnGermany
  10. 10.Medical Genetics Research Program and Dept. of Psychiatry and Behavioral SciencesSUNY Upstate Medical UniversitySyracuseUSA
  11. 11.Dept. of Clinical Neuropsychology, Faculty of Psychology & EducationVrije UniversitatAmsterdamThe Netherlands
  12. 12.Dept. of Child & Adolescent PsychiatryUniversity of ZurichZürichSwitzerland
  13. 13.Dept. of PsychologyUniversity of SouthamptonSouthamptonUK
  14. 14.Dept. of Child & Adolescent Psychiatry, Institute of PsychiatryKings College LondonLondonUK

Personalised recommendations